Visceral leishmaniasis with cutaneous symptoms in a patient treated with infliximab followed by fatal consequences

Dermatologic Therapy

Volumn 27, Issue 3, 2014, Pages 131-134

  Juzlova, Katerina ^a   Votrubova, Jana ^a   Kacerovska, Denisa ^a   Lukas, Milan ^a   Bortlik, Martin ^a   Rohacova, Hana ^b   Nohynkova, Eva ^a   Vojackova, Nadezda ^a   Fialova, Jorga ^a   Hercogova, Jana ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

Author keywords

immunosuppression; skin manifestation; visceral leishmaniasis

Indexed keywords

FLUCONAZOLE; INFLIXIMAB; INTERNAL TRANSCRIBED SPACER; MEGLUMINE ANTIMONATE; ANTIINFLAMMATORY AGENT; ANTIPROTOZOAL AGENT; GASTROINTESTINAL AGENT; MEGLUMINE; MEGLUMINE ANTIMONIATE; MONOCLONAL ANTIBODY; ORGANOMETALLIC COMPOUND;

ADULT; ARTICLE; CASE REPORT; CROHN DISEASE; FUNGUS HYPHAE; FUNGUS SPORE; HEART ARRHYTHMIA; HUMAN; HUMAN TISSUE; IMMUNOCOMPROMISED PATIENT; LICHEN PLANUS; MALE; POLYMERASE CHAIN REACTION; SKIN MANIFESTATION; SUPERFICIAL MYCOSIS; VISCERAL LEISHMANIASIS; CHEMICALLY INDUCED; FATALITY; IMMUNOLOGY; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; PARASITOLOGY;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIPROTOZOAL AGENTS; ARRHYTHMIAS, CARDIAC; CROHN DISEASE; FATAL OUTCOME; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOCOMPROMISED HOST; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS;

EID: 84902107588     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/dth.12083     Document Type: Article

References (15)

1. Bogdan C,. Leishmaniasis in rheumatology, haematology and oncology: epidemiological, immunological and clinical aspects and caveats. Ann Rheum Dis 2012: 71 (Suppl. 2): i60-i66.
2. Rosenthal E, Marty P,. Recent understanding in the treatment of visceral leishmaniasis. J Postgrad Med 2003: 49: 61-68.
3. Gradoni L, Gramiccia M, Scalone A,. Visceral leishmaniasis treatment, Italy. Emerg Infect Dis 2003: 9 (12): 1617-1620.
4. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J,. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 2003: 22: 434-438.
5. Paris C, Loiseau PM, Bories C, Bréard J,. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2004: 48: 852-859.
6. Sindermann H, Croft SL, Engel KR, et al. Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med Microbiol Immunol (Berl) 2004: 193: 173-180.
7. More B, Bhatt H, Kukreja V, Ainapure SS,. Miltefosine: great expectations against visceral leishmaniasis. J Postgrad Med 2003: 49: 101-103.
8. Prasad R, Kumar R, Jaiswal BP, Singh UK,. Miltefosine: an oral drug for visceral leishmaniasis. Indian J Pediatr 2004: 71: 143-144.
9. Ovesen A,. Perianal Buschke-Löwenstein tumour. Ugeskr Laeger 2012: 174 (23): 1616-1617.
10. Skerlev M, Ljubojevic S,. The specifities of the HPV-genital infections in males. Med Glas Ljek komore Zenicko-doboj kantona 2010: 7 (2): 89-95.
11. Bonheur JL, Braunstein J, Korelitz BI, Panagopoulos G,. Anal skin tags in inflammatory bowel disease: new observations and a clinical review. Inflamm Bowel Dis 2008: 14: 1-6.
12. Danden E, Peñas PF, Rios L, et al. Leishmania presenting as dermatomyositis-like eruption in AIDS. J Am Acad Dermatol 1996: 35: 316-319.
13. Perrin C, Taillan B, Hofman P, Mondain V, Lefichoux Y, Michiels JF,. Atypical cutaneous histopathological features of visceral leishmaniasis in acquired immunodeficiency syndrome. Am J Dermatopathol 1995: 17: 145-150.
14. Colebunders R, Depraetera K, Verstraeten T, et al. Unusual cutaneous lesions in two patients with visceral leishmaniasis and HIV infection. J Am Acad Dermatol 1999: 41: 847-850.
15. Santos-Oliveira JR, Da-Cruz AM, Pires LH, et al. Atypical lesions as a sign of cutaneous dissemination of visceral leishmaniasis in a human immunodeficiency virus-positive patient simultaneously infected by two viscerotropic Leishmania species. Am J Trop Med Hyg 2011: 85 (1): 55-59.